Statin use and association with colorectal cancer survival and risk: Case control study with prescription data linkage

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Lakha, Fatim ^a   Theodoratou, Evropi ^a   Farrington, Susan M ^a   Tenesa, Albert ^a   Cetnarskyj, Roseanne ^b   Din, Farhat V N ^a   Porteous, Mary E ^c   Dunlop, Malcolm G ^a   Campbell, Harry ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b EDINBURGH NAPIER UNIVERSITY   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CASE CONTROL STUDY; CAUSE OF DEATH; CHILD; COLORECTAL CANCER; CONTROLLED STUDY; DIET; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; SCHOOL CHILD; UNITED KINGDOM;

CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK; SCOTLAND;

EID: 84867641427     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-487     Document Type: Article

References (32)

1. ISD Cancer in Scotland. [online] 2011, NHS National Services Scotland, Available at: http://www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/Cancer_in_Scotland_summary_m.pdf [accessed 03.10.12], ISD.
2. Maron D, Fazio S, Linton M. Current Perspectives on Statins. Circulation 2000, 101:207-213.
3. Katz M, Minsky B, Saltz L, Riedel E, Chessin D, et al. Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. International Journal of Radiation Oncology Biol Phys 2005, 62:1363-1370.
4. Hunninghake D. HMG-CoA reductase inhibitors. Curr Opin Lipidol 1992, 3:22-28.
5. Stancu C, Sima A. Statins: mechanism of action and effects. Journal of Cellular and Molecular Medicine 2001, 5:378-387.
6. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering-are they clinically relevant? [Review] [208 refs]. Eur Hear J 2003, 24:225-248.
7. Sleijfer S, van der Gaast A, Planting AST, Stoter G, Verweij J. The potential of statins as part of anti-cancer treatment. Eur J Cancer 2005, 41:516-522.
8. Jakobisiak M, Golab J. Potential antitumor effects of statins (Review). Internatinal Journal of Oncology 2003, 23:1055-1069.
9. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins. Annals of Medicine 2000, 32:164-176.
10. Chan KKW, Oza AM, Siu LL. The Statins as Anticancer Agents. Clin Cancer Res 2003, 9:10-19.
11. Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treatment Reviews 2004, 30:609-641.
12. Narisawa T, Fukaura Y, Tanida N, Hasebe M, Ito M, et al. Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice. Tohoku J Exp Med 1996, 180:131-138.
13. Narisawa T, Fukaura Y, Terada K, Umezawa A, Tanida N, et al. Prevention of 1,2-Dimethylhydrazine-Induced Colon Tumorigenesis by Hmg-Coa Reductase Inhibitors, Pravastatin and Simvastatin, in Icr Mice. Carcinogenesis 1994, 15:2045-2048.
14. Narisawa T, Morotomi M, Fukaura Y, Hasebe M, Ito M, et al. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Japanese Journal of Cancer Research 1996, 87:798-804.
15. Suzuki S, Tajima T, Sassa S, Kudo H, Okayasu I, et al. Preventive effect of fluvastatin on ulcerative colitis-associated carcinogenesis in mice. Anticancer Res 2006, 26:4223-4228.
16. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, et al. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 1999, 5:2223-2229.
17. Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, Czajka A, Switaj T, et al. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res 2000, 6:2044-2052.
18. Jin Z, Dicker D, El-Deiry W. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL, Cell Cycle 1 (2002), pp. 82-89. Cell Cycle 2002, 1:82-89.
19. Kim KP, Whitehead C, Piazza G, Wargovich MJ. Combinatorial chemoprevention: Efficacy of lovostatin and Exisulind on the formation and progression of aberrant crypt foci. Anticancer Res 2004, 24:1805-1811.
20. Swamy MV, Patlolla JMR, Steele VE, Kopelovich L, Reddy BS, et al. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APC(min) mice. Cancer Res 2006, 66:7370-7376.
21. Xiao H, Zhang Q, Lin Y, Reddy BS, Yang CS. Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer 2008, 122:2115-2124.
22. Coogan P, Smith J, Rosenberg L. Statin use and the risk of colorectal cancer. Journal of the National Cancer Institute 2007, 99:32-40.
23. Siddiqui AA, Nazario H, Mahgoub A, Patel M, Cipher D, et al. For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. Dig Dis Sci 2009, 54:1307-1311.
24. Theodoratou E, Kyle J, Cetnarskyj R, Farrington S, Tenesa A, et al. Dietary Flavanoids and the Risk of Colorectal Cancer. Cancer Epidemiology Biomarkers & Prevention 2007, 16:684-693.
25. Masson L, McNeill G, Tomany J, Simpson J, Peace H, et al. Statistical approaches for assessing the relative validity of a food-frequency questionnaire: use of correlation coefficients and the kappa statistic. Public Health Nutrition 2003, 6:313-321.
26. Jia X, Craig L, Aucott L, Milne A, McNeill G. Repeatability and validity of a food frequency questionnaire in free-living older people in relation to cognitive function. J Nutr Health Aging 2008, 12:735-741.
27. Zielinski S. Following positive epidemiologic studies, statins to enter clinical trials for cancer prevention. Journal of the National Cancer Institute 2005, 97:1172-1173.
28. Poynter JN, Gruber SB, Higgins PDR, Almog R, Bonner JD, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005, 352:2184-2192.
29. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004, 90:635-637.
30. Graaf MR, Beiderbeck AB, Egberts ACG, Richel DJ, Guchelaar H-J. The Risk of Cancer in Users of Statins. J Clin Oncol 2004, 22:2388-2394.
31. No authors listed. A role for statins in chemoprevention. The Lancet Oncology 2004, 5:391.
32. Moorman PG, Hamilton RJ. Statins and cancer risk - What do we know and where do we go from here?. Epidemiology 2007, 18:194-196.